Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07645651 · ClinicalTrials.gov registry record · Phase 1
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
A Phase 1 study, sponsored by University of Washington.
- Not yet
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT07645651 is a Phase 1 study that has not yet begun recruiting, run by University of Washington. The registered enrollment target is 15 participants.
The verdict
NCT07645651, a Phase 1 study, has not yet begun recruiting, sponsored by University of Washington.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- DRUG Samuraciclib
- PROCEDURE Endoscopic Ultrasound Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07645651
The ClinicalTrials.gov registry entry for NCT07645651 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT07645651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07645651 about?
NCT07645651 is a clinical study titled "Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer". The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.
What is the current status of trial NCT07645651?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-07-01. Estimated completion is 2027-11-01.
What interventions are being tested in trial NCT07645651?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Samuraciclib (DRUG), Endoscopic Ultrasound Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT07645651?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.